Newsfeeds - Spark Newswire

2 minute read

SCYNEXIS To Present Pooled Data Analysis Results Demonstrating Consistent Efficacy And Safety Outcomes Across Two Phase 3 VANISH Clinical Trials Of Oral Ibrexafungerp Therapy For Vaginal Yeast Infection At October Medical Conferences

Today, 7:10 PM

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced presentations of a pooled data analysis from

SCYX

2 minute read

SCYNEXIS Highlights Presentation Of Preclinical Data Supporting Potential Of Ibrexafungerp To Treat Mucormycosis

By Benzinga Newsdesk

Today, 7:10 PM

SCYX

1 minute read

Events
News

SCYNEXIS To Present Clinical Data From Ongoing FURI And CARES Studies At The 10th Trends In Medical Mycology Meeting Showing Oral Ibrexafungerp Provides A Favorable Therapeutic Response In Patients With Severe Fungal Infections

By Benzinga Newsdesk

Today, 7:10 PM

SCYX

1 minute read

Scynexis Presents Interim Ibrexafungerp Data In Hospital-Based Fungal Infections

By Vandana Singh

Today, 7:10 PM

Scynexis Inc (NASDAQ:SCYX) announced an oral presentation of interim data analyses from its ongoing Phase 3 FURI study of oral ibrexafungerp…

SCYX

1 minute read

SCYNEXIS Q2 EPS $(0.22) Up From $(0.64) YoY

By Bill Haddad

Today, 7:10 PM

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.22) per share. This is a 65.63 percent increase over losses of $(0.64) per share from the same period last year.

SCYX

1 minute read

News

SCYNEXIS Announces Three Oral Presentations Of Ibrexafungerp Demonstrating Clinical And In Vitro Activity Against Candida Species At The 31st ECCMID

By Benzinga Newsdesk

Today, 7:10 PM

FURI and CARES presentations show ibrexafungerp’s strong clinical response in difficult-to-treat and refractory fungal infections in the hospital setting including Candida auris In vitro data demonstrates

SCYX

5 minute read

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates

By Shanthi Rexaline

Today, 7:10 PM

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.

ALBO

1 minute read

FDA
News

SCYNEXIS Reports Will Launch Update For BREXAFEMME; To Host Call Tuesday, Jun. 29 At 12 p.m. EDT

By Benzinga Newsdesk

Today, 7:10 PM

BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal

SCYX

5 minute read

66 Biggest Movers From Yesterday

By Lisa Levin

Today, 7:10 PM

Gainers

AMC

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 7:10 PM

BPTH